ANE 2023 Poster C037

Large Scale Organoid Panel Drug Screening to Short-track Clinically-relevant Output

Liza Wijler, Annelot Staes, Linda van Seters, Lama Hasan, Bram Herpers, Leo Price, Mariusz Madej, Michiel Fokkelman, Xiaoxi Xu, and Marrit Putker

Crown Bioscience Netherlands BV, Yalelaan 42, 3584 CM Utrecht, The Netherlands

Patient-derived organoids (PDOs) have emerged as representative in vitro replicas of tumor biology, bringing increased accuracy in predicting clinical outcomes based on pre-clinical results.

Large and deeply characterized organoid biobanks, covering broad varieties of indications and genetic backgrounds, have been generated that allow large scale (combination) drug testing, reliable biomarker predictions, improved drug repurposing, and patient stratification studies.

Relatively longer lead-in timelines and higher complexity compared to other in vitro models currently hold the organoids back. To overcome these hurdles, we have improved the logistics of our pipeline and here present a large-scale organoid panel drug screening platform consisting of over 50 organoid models for drug response prediction across seven indications in a robust but also fast and cost-efficient assay.

Download this Poster to Discover:

• How Assay-ready organoid technology-based large scale panel screening, has resulted in increased efficiency and up to 8 times reduced timeline, which will therefore further harness the large potential of PDO technology in the drug development pipeline.
  
  
• How a novel panel screen experimental set-up increased assay consistency and reproducibility.
  
  
• How combining panel screens with advanced biomarker analysis will allow early patient stratification, further aiding the clinical development of novel oncology drugs.

Download the Poster Now!